In:
Stroke, Ovid Technologies (Wolters Kluwer Health), Vol. 49, No. Suppl_1 ( 2018-01-22)
Abstract:
Purpose: Reperfusion injury after thrombolytic therapy or mechanical thrombectomy would adverse neurological outcome. Generation of reactive oxygen species (ROS) due to reperfusion is relevant for aggravation. The development of drug therapy for scavenging free radical is expected to lead to better neurological prognosis. We developed a new core-shell type nanoparticle, RNP (radical containing nanoparticle), which consists of micelle containing 4-amino-TEMPO. The purpose of this study is to evaluate an efficacy of intra-arterial injection of RNP after reperfusion using tMCAO mice model. Methods: C57BL/6J mice underwent tMCAO for 60 minutes and received RNP by intra-arterial injection from common carotid artery. We evaluated infarction size, neurological scale, and Evans blue extravasation at 24h after reperfusion. RNP distribution was detected by rhodamine labeling. We further examined immunofluorescense of CD31, Occludin, TUNEL, dihydroethydium, and 8-hydroxy-deoxyguanosine (8-OHdG). Multiple free radical scavenging capacity of ischemic hemisphere was analyzed by Electron Paramagnetic Resonance (EPR). Results: RNPs were detected in endothelial cells and around neuronal cells in the ischemic lesion. The infarction size, neurological scale, Evans blue extravasation of the mice treated by RNP were significantly lower than the mice treated by PBS , control group. Intra-arterial RNP treatment preserved endothelium and expression of occludin in the ischemic brain. Further, apoptosis of neuronal cells and production of superoxide anions and 8OHdG were suppressed. By using EPR, multiple ROS scavenging capacity (•OH, •ROO, •O 2 - ) of the ischemic brain treated by RNP were higher. Conclusions: These results suggest that intra-arterial injection of RNP have efficacy of neurovascular unit protection and reduce infarction volume by improving multiple ROS scavenging capacity.
Type of Medium:
Online Resource
ISSN:
0039-2499
,
1524-4628
DOI:
10.1161/str.49.suppl_1.WMP119
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2018
detail.hit.zdb_id:
1467823-8
Permalink